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Edited by Masayuki MiyasakaAbstract Epidermal keratinocytes with atopic dermatitis (AD)
overproduce mediators such as granulocyte macrophage colony-
stimulating factor (GM-CSF), which are associated with
pathology of AD. We found that peptidoglycan (PGN) of
Staphylococcus aureus, which is frequently observed in lesion
with AD, induced the production of numerous mediators such as
GM-CSF and regulated on activation, normal T-cell expressed
and secreted. Moreover, PGN phosphorylated extracellular-
signal-regulated kinases and p38 mitogen-activated protein
kinase, which were involved in the induction of GM-CSF
expression. These results suggested that PGN of S. aureus
directly exacerbates inﬂammation of inﬂammatory skin disease.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Atopic dermatitis (AD) is a chronic inﬂammatory skin dis-
ease with a tendency for exacerbation and remission over time
[1]. Patients with AD show higher levels and synthesis of cy-
tokines, such as interleukin (IL)-4, IL-5 and granulocyte
macrophage colony-stimulating factor (GM-CSF), in their
skin lesions [1]. IL-4 and IL-5, which are derived from the
inﬁltrated Th2 cells and mast cells, are well known to induce
the IgE class switching in B cells and eosinophilia, respectively
[1]. IL-4 plays important roles in the induction of acute re-
sponse whereas IL-5 and GM-CSF are involved in chronic
inﬂammation of AD [1]. GM-CSF is locally critical in devel-
opment and function of antigen-presenting dendritic cells (DC)
and Langerhans cells (LC) [2–5]. GM-CSF also inhibits the
production of Th-1-inducing cytokine IL-12 from LC [6]. In-
crease in GM-CSF production correlates with accumulation
and activation of DC and LC in lesional skin with AD [1].
Therefore, excessive GM-CSF production is suggested to cause* Corresponding author. Fax: +81-559-86-7430.
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sponse [6].
Although GM-CSF is especially produced from epidermal
keratinocytes with AD [2], the mechanisms for enhanced GM-
CSF production remains fully understood. Keratinocytes not
only constitute the major epidermal cell population as a
physical barrier but also synthesize several cytokines and
chemokines, such as GM-CSF and regulated on activation,
normal T-cell expressed and secreted (RANTES), which are
responsible for the skin immune response [2,7–10]. However,
abnormal production of cytokines and chemokines including
GM-CSF is believed to participate in inﬂammation of skin
disorders [2,7].
Increased numbers of Staphylococcus aureus are found in
over 90% of AD skin lesions [1]. S. aureus thus is suggested to
amplify the skin inﬂammation by superantigens such as
staphylococcal entertoxins A and B, which target on several
types cells such as keratinocytes to continue T-cell activation
and release of pro-inﬂammatory mediators [11]. Recently,
peptidoglycan (PGN), which predominates the cell wall of S.
aureus, has been demonstrated to activate nuclear factor-jB
(NF-jB) and induce abundantly IL-8 production from kerat-
inocytes via functionally toll-like receptor 2 (TLR2) [12–14].
Activation of pathways of NF-jB and mitogen-activated
protein kinases (MAPKs) is involved in several biological re-
sponses of keratinocytes [12,13,15–17]. These ﬁndings suggest
that PGN play major roles in the production of cytokines and
chemokines from keratinocytes.
In the present study, we investigated whether or not PGN
induces the release of GM-CSF and activate MAPKs using
human epidermal keratinocytes. Moreover, we also examined
eﬀects of PGN on the expression of other keratinocyte-
derived mediators, as described below. Several chemokines,
such as RANTES, monocyte chemoattractant protein-1
(MCP-1) and IL-8, are highly expressed in lesion site with
AD or psoriasis and stimulate the migration of many types of
cell. Intracellular adhesion molecule-1 (ICAM-1), a potent
adherent molecule between T lymphocyte and keratinocyte,
acts as a co-stimulant of the activation of T lymphocyte [20].
Tumor necrosis factor (TNF)-a and IL-6 are involved in
migration of LC in skin inﬂammation [21]. Substance P, a
product of preprotachykinin A gene, is discussed the rele-
vance with skin disorder because it degranulates mast cell,
causing itchy feelings [10].blished by Elsevier B.V. All rights reserved.
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2.1. Materials
Olopatadine hydrochloride was synthesized in our laboratories. The
following materials were purchased from the indicated commercial
source: PD98059 (Cell Signaling); SB203580 (Calbiochem); S. aureus-
derived PGN (Sigma–Aldrich); histamine (Sigma); recombinant human
TNF-a (Strathmann Biotic); recombinant human IL-4 (Chemi-Con);
and recombinant human IFN-c (Strathmann Biotec). Olopatadine hy-
drochloride, PD98059 and SB203580 were dissolved in dimethyl sulf-
oxide at a concentration of 0.1 mol/L and stored at )20 C before use.
The ﬁnal concentration of dimethyl sulfoxide in the assay system de-
scribed below was 0.1 v/v%.
2.2. Cell culture
Primary human epidermal keratinocytes were purchased from Bio-
whittaker and grown in KGM-2 with the addition of supplement
containing bovine pituitary extract, human epidermal growth factor,
insulin, epinephrine, transferrin, hydrocortisone, gentamycin and am-
photericin B according to the manufacturer’s instruction (Clonetics).
Cells were cultured at conﬂuent state. After the cells were rapidly
washed with Dulbecco’s modiﬁed Eagle’s medium (Nissui), they were
resuspended in KGM-2 medium without hydrocortisone the day be-
fore assay. Cells between passages 3 and 6 were used.
2.3. Semi-quantiﬁcation of mRNA by reverse transcription-polymerase
chain reaction (RT-PCR)
Conﬂuent cells in 6-well plates were treated with the indicated
concentrations of agents for 0.5 h in KGM-2 without hydrocortisone
and then stimulated with 30 lg/mL PGN for a given length of time.
Total RNA was isolated according to the manufacturer’s instruction
(RNeasy, Qiagen). First strand-cDNA synthesis was performed from
1.5 lg of total RNA in 20 lL volumes with oligo(dT) priming using the
Superscript First-strand Synthesis System (invitrogen). PCR was per-
formed from the generated cDNA using ExTaq polymerase (Takara).
Based on previous reports [22–25], the following primer pairs (in-
cluding PCR product sizes in parentheses) were synthesized by Invit-
rogen: TLR2, 50-GCC AAA GTC TTG ATT GAT TGG-30 and
50-TTG AAG TTC TCC AGC TCC TG-30 (347 bp); TLR4, 50-TGG
ATA CGT TTC CTT ATA AG-30 and 50-GAA ATG GAG GCA
CCC CTT C-30 (507 bp); GM-CSF, 50-GGC GTC TCC TGA ACC
TGA GTA G-30 and 50-GTC GGC TCC TGG AGG TCA AA-30 (91
bp); RANTES, 50-TCC CCA TAT TCC TCG GAC-30 and 50-GAT
GTA CTC CCG AAC CCA-30 (186 bp); TNF-a, 50-AAG ACC TCA
CCT AGA AAT TGA CAC-30 and 50-TAG GCC GAT TAC AGA
CAC AAC-30 (419 bp); IL-6, 50-TGA CAA CTC ATC TCA TTC
TGC-30 and 50-AAG TTA GCC ATT TAT TTG AGG TAA GC-30
(411 bp); IL-8, 50-CTA GCC AGG ATC CAC AAG TCC-30 and 50-
AGC ACT ACC AAC ACA GCT GGC-30 (503 bp); MCP-1, 50-CAG
CCA GAT GCA ATC AAT GC-30 and 50-GTG GTC CAT GGA
ATC CTG AA-30 (198 bp); ICAM-1, 50-TAT GGC AAC GAC TCC
TTC T-30 and 50-CAT TCA GCG TCA CCT TGG-30 (238 bp); PPTA,
50-GAC AGC GAC CAG ATC AAG GAG GAA-30 and 50-CAG
CAT CCC GTT TGC C-30 (115 bp); glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH), 50-CCC ATC ACC ATC TTC CAG GAG-30
and 50-TTC ACC ACC TTC TTG ATG TCA-30 (572 bp). The de-
naturation, annealing, and extension conditions for TLR2, TLR4,
GM-CSF, RANTES, IL-8, MCP-1, ICAM-1, PPTA and GAPDH
were 94 C for 60 s, 60 C for 45 s and 72 C for 45 s, respectively, and
that for TNF-a and IL-6 were 94 C for 30 s, 65 C for 30 s and 72 C
for 30 s, respectively. The PCR cycle conditions were 30, 35, 27, 27, 32,
33, 22, 29, 25, 33 and 19 cycles for TLR2, TLR4, GM-CSF, RANTES,
TNF-a, IL-6, IL-8, MCP-1, ICAM-1, PPTA and GAPDH, respec-
tively. These conditions are the optimal settings for each gene. PCR
was performed with a GeneAmp PCR system 9700 (Applied Biosys-
tems). The PCR products were electrophoresed in 2% w/v agarose gels
and stained with SYBRGreen I (Molecular Probes). The detection and
densitometric analysis of band were performed with a Lumino Image
Analyzer LAS-1000 plus (Fujiﬁlm).2.4. Western blot analysis
Conﬂuent cells in 6-well plates were treated with the indicated
concentrations of agents for 0.5 h in KGM-2 without hydrocortisone,
and then stimulated with 30 lg/mL PGN for a given length of time.The cells were lysed with ice-cold lysis buﬀer (150 mmol/L NaCl, 1
mmol/L Na2EDTA, 1 mmol/L EGTA, 1 v/v% Triton X-100, 2.5 mmol/
L sodium pyrophosphate, 1 mmol/L b-glycerophosphate, 1 mmol/L
Na3VO4, 1 lg/mL leupeptin, 10 mmol/L NaF, 1 mmol/L phenyl-
methylsulfonyl ﬂuoride, 20 mmol/L Tris–HCl, pH 7.5) for 30 min on
ice. Insoluble material was removed by centrifugation and the super-
natant was boiled with Laemmli’s buﬀer containing dithiothreitol for 3
min. Equivalent contents of protein in each sample (10 lg/lane) were
separated by 7.5 or 10% SDS–PAGE and blotted onto a PVDF
membrane (Immobilon, Millipore). Proteins were detected using an
immunoblotting technique with the following antibodies: anti-TLR2
antibody (Santa Cruz); anti-actin antibody (Santa Cruz); anti-ERK-1/
2 antibody (Cell Signaling); anti-phospho-ERK-1/2 antibody (Cell
Signaling); anti-phospho-p38 MAP kinase antibody (Cell Signaling);
anti-phospho-JNK-1/2 antibody (Cell Signaling); and anti-phospho-
ATF-2 antibody (Cell Signaling). Horseradish peroxidase-linked whole
antibody (Amersham Bioscience) was used as a secondary antibody.
The antibodies were detected with Super Signal West Pico Chemilu-
minescent Substrate (Pierce) and analyzed using a Lumino Image
Analyzer LAS-1000 Plus (Fujiﬁlm).
2.5. Measurement of mediator production
Conﬂuent cells in 24-well plates were treated with the indicated
concentrations of agents for 0.5 h in KGM-2 without hydrocortisone
and then stimulated with 30 lg/mL PGN for a given length of time.
GM-CSF, RANTES, TNF-a, IL-6, or IL-8 levels in the supernatant
were determined using commercially available ELISA according to the
manufacturer’s instructions. The applied ELISA kits were human GM-
CSF AN’ALYZA (Genzyme/Teche), human RANTES Duo Set (R&D
Systems), Human TNF-a US Kit (BioSource), Endogen Human IL-6
(PIERCE) and human IL-8 Duo Set (R&D Systems).
2.6. Cell surface ELISA for determination of ICAM-1
Conﬂuent cells were cultured in 96-well plates. After stimulation, the
mediumwas removedand the cellswereﬁxedwith3.7%formaldehydeon
icefor30min.Theplateswerethenwashedwithphosphate-buﬀeredsaline
and blocked with 1% w/v BSA on ice for 1 h. A primary anti-ICAM-1
antibody (Cymbus Biotechnology) was added and incubated on ice for
1 h. The plates were then washed and incubated with horseradish perox-
idase-conjugated anti-mouse secondary antibody on ice for 1 h. After
incubation, the plates were washed again. The antibodies were detected
with Super Signal West Pico Chemiluminescent Substrate using Micro-
plate Scintillation&Luminescence Counter TopCountNXT (Packard).
2.7. Statistical analysis
Statistical analysis was performed using the Dunnett test. P values<
0.05 were considered signiﬁcant.3. Results
3.1. Eﬀects of PGN on mRNA expression and protein
production of GM-CSF
We conﬁrmed that mRNA and protein of TLR2 was ex-
pressed in cultured human epidermal keratinocytes whereas
mRNA of TLR4 was not (Fig. 1A and B), in agreement with
previous study [12]. Treatment with S. aureus-derived PGN-in-
ducedmRNA expression of GM-CSF (Fig. 1C). The expression
was temporary and peaked at 1 or 2 h after stimulation. PGN
increased inGM-CSFmRNA levelsmore potently thanTNF-a,
IL-4 and IFN-c (Fig. 1D). Furthermore, PGN increased inGM-
CSF production in a concentration- and time-dependent man-
ner (Fig. 1E andF). Elevation ofGM-CSF production as well as
mRNA expression induced by PGN was more signiﬁcant than
that by TNF-a, IL-4 and IFN-c (Fig. 1F).
3.2. Eﬀects of PGN on mRNA expression and protein
production of RANTES
Treatment with PGN also induced mRNA expression
of RANTES (Fig. 2A). The increase in mRNA levels was
Fig. 1. PGN-induced GM-CSF expression and production in cultured
keratinocytes. (A) Expression of TLR2 and TLR4 mRNA was ana-
lyzed by RT-PCR with speciﬁc primer sets. RT negative samples were
included as control for the genomic contamination. (B) Total cell ly-
sate was analyzed by Western blotting with an anti-human TLR2
antibody. The arrow shows apparent molecular mass 90 kDa for
TLR2. (C) Keratinocytes were stimulated with 100 lg/mL PGN. Time
course of GM-CSF mRNA levels was analyzed with the semi-quan-
titative RT-PCR method. One representative result of three indepen-
dent experiments is shown. (D) Keratinocytes were stimulated with 100
lg/mL PGN (b), 100 ng/mL TNF-a (c), 100 ng/mL IL-4 (d) or 100 ng/
mL IFN-c (e) for 2 h. An unstimulated sample is (a). GM-CSF mRNA
level in each sample was analyzed. One representative result of two
independent experiments is shown. (E) Keratinocytes were stimulated
with 30 lg/mL PGN. Time course of GM-CSF released into the su-
pernatant was measured by ELISA. Values represent means S.E. of
three determinations. (F) Keratinocyte were stimulated with the indi-
cated concentrations of PGN, 100 ng/mL TNF-a, 100 ng/mL IL-4 or
100 ng/mL IFN-c for 8 h. Amount of GM-CSF in each sample was
measured. Values represent means S.E. of three determinations.
Fig. 2. PGN-induced RANTES expression and production in cultured
keratinocytes. (A) Keratinocytes were stimulated with 100 lg/mL
PGN. Time course of RANTES mRNA levels was analyzed with the
semi-quantitative RT-PCR method. One representative result of two
independent experiments is shown. (B) Keratinocytes were stimulated
with 100 lg/mL PGN (b), 100 ng/mL TNF-a (c), 100 ng/mL IL-4 (d) or
100 ng/mL IFN-c (e) for 2 h. An unstimulated sample is (a). RANTES
mRNA level in each sample was analyzed. One representative result of
two independent experiments is shown. (C) Keratinocytes were stim-
ulated with 30 lg/mL PGN. Time course of RANTES released into the
supernatant was measured by ELISA. Values represent meansS.E.
of three determinations. (D) Keratinocyte were stimulated with the
indicated concentrations of PGN, 100 ng/mL TNF-a, 100 ng/mL IL-4
or 100 ng/mL IFN-c for 8 h. Amount of RANTES in each sample was
measured. Values represent meansS.E. of three determinations.
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increased in mRNA levels and production of RANTES more
potently than TNF-a, IL-4 and IFN-c (Fig. 2B–D).3.3. Eﬀects of PGN on expression and production of various
keratinocyte-derived mediators
mRNA expression of TNF-a, IL-6, IL-8, MCP-1, ICAM-1
and PPTA other than GM-CSF and RANTES was also up-
regulated by PGN (Fig. 3A). Time course of maximal induc-
tion diﬀered among these mediators. Moreover, PGN also
stimulated protein production of TNF-a, IL-6, IL-8 and
ICAM-1 (Fig. 3B).3.4. Involvement of ERK and p38 MAPK in PGN-induced
GM-CSF production
Since MAPKs are involved in several biological responses
[15–17], we examined whether or not PGN phosphorylates
MAPKs, such as ERK-1/2, p38 MAPK and JNK-1/2. ERK-1/
2, p38 MAPK and JNK-1/2 were weakly phosphorylated by
control medium itself and then addition of PGN to control
medium enhanced the phosphorylation of these MAPKs(Fig. 4A). PGN increased in the phosphorylated MAPKs more
potently than TNF-a, IL-4 and IFN-c (Fig. 4B). Moreover,
PGN and TNF-a also phosphorylated activating transcrip-
tional factor 2 (ATF2), which is downstream of p38 MAPK
(Fig. 4B). We examined the roles of ERK and p38 MAPK
pathways on PGN-induced GM-CSF production by pharma-
cological study using the selective inhibitor of MEK-1 and p38
MAPK, PD98059 and SB203580, respectively. PD98059 sup-
pressed phosphorylation of ERK whereas SB203580 reduced
phosphorylation of p38 MAPK and its downstream ATF2
(Fig. 5A). Pretreatment with PD98059 or SB203580 inhibited
the increase in GM-CSF mRNA levels 2 h after stimulation
(Fig. 5B). In addition, both inhibitors also concentration-
dependently inhibited GM-CSF production (Fig. 5C). Sup-
pression by SB203580 of expression and production of
GM-CSF was more eﬀective than that by PD98059.
3.5. Coordinative eﬀects on PGN and histamine on GM-CSF
production
Since number of mast cell is increased in lesion of AD [1]
and histamine has been reported to activate ERK via hista-
mine H1 receptor in epidermal keratinocytes [8], eﬀects of
histamine on mRNA expression of GM-CSF were also ex-
amined. As expected, histamine-induced GM-CSF expression
(Fig. 6A), and then its expression was prevented by the ap-
plication of olopatadine hydrochloride, an anti-allergic drug
with selective histamine H1 receptor antagonism [26] (Fig. 6B).
This drug did not aﬀect PGN-induced GM-CSF expression
(data not shown). Histamine concentration-dependently stim-
ulated GM-CSF production (Fig. 6C). Moreover, coadminis-
tration with histamine and PGN augmented GM-CSF
production compare with sole stimulation (Fig. 6D).
Fig. 3. PGN-induced expression and production of various mediators in cultured keratinocytes. (A) Keratinocytes were stimulated with 100 lg/mL
PGN. Time course of the indicated mediator mRNA levels was analyzed with the semi-quantitative RT-PCR method. One representative result of
two independent experiments is shown. (B) Keratinocyte were stimulated with the indicated concentrations of PGN, 100 ng/mL TNF-a, 100 ng/mL
IL-4 or 100 ng/mL IFN-c for 8 h. Amount of the indicated mediator in each sample was measured by ELISA. Values represent means S.E. of three
determinations.
Fig. 5. Involvement of ERK and p38 MAPK in PGN-induced GM-
CSF production. (A) Keratinocytes were pretreated with 10 lmol/L
PD98059 and 10 lmol/L SB203580 for 30 min prior to stimulation
with 30 lg/mL PGN for 30 min (A), 2 h (B) or 24 h (C). (A) Phos-
phorylation of ERK1/2, p38 MAPK and ATF-2 was detected by
Western blotting using phospho-protein speciﬁc antibodies. (B) The
GM-CSF mRNA level in each sample was analyzed with the
semi-quantitative RT-PCR method. (C) Amount of GM-CSF in su-
pernatant was measured. Values represent meansS.E. of three de-
terminations. *P < 0:05, **P < 0:01, ***P < 0:001 compared with the
control group (Dunnett).
Fig. 4. PGN-induced phosphorylation of MAPKs in cultured kerati-
nocytes. (A) Keratinocytes were stimulated with 100 lg/mL PGN.
Phosphorylation of ERK1/2, p38 MAPK and JNK1/2 was detected by
Western blotting using phospho-protein speciﬁc antibodies. Time
course of phosphorylation levels is shown. (B) Keratinocytes were
stimulated with 30 lg/mL PGN (b), 100 ng/mL TNF-a (c), 100 ng/mL
IL-4 (d) or 100 ng/mL IFN-c (e) for 30 min. An unstimulated sample
is (a). The indicated phospho-protein levels in each sample were
analyzed.
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In the present study, we demonstrated that PGN, a main
constituent of outer membrane of S. aureus, induced expres-
sion and production of GM-CSF from human epidermal
keratinocytes. Elevation of expression and production of GM-
CSF by PGN was the most potent among stimulants (e.g.,
TNF-a). Furthermore, PGN also stimulated the expression or
production of numerous keratinocyte-derived mediators suchas RANTES, TNF-a, IL-6, IL-8, MCP-1, ICAM-1 and PPTA,
which are believed to contribute to skin disorders. Since ke-
ratinocytes express TLR2, which is essential recognition of
Fig. 6. Histamine- and PGN-induced GM-CSF production in cultured
keratinocytes. (A) Keratinocytes were stimulated with 10 lmol/L his-
tamine. Time course of GM-CSF mRNA levels was analyzed with the
semi-quantitative RT-PCR method. One representative result of two
independent experiments is shown. (B) Keratinocytes were pretreated
with 1 lmol/L of a selective histamine H1 receptor antagonist, olo-
patadine hydrochloride, for 30 min prior to stimulation with 10 lmol/
L histamine for 2 h. GM-CSF mRNA level in each sample was ana-
lyzed. One representative result of two independent experiments is
shown. (C) Keratinocytes were stimulated with the indicated concen-
tration of histamine for 24 h. Amount of GM-CSF in supernatant
histamine and 10 lg/mL PGN for 24 h. Amount of GM-CSF in each
sample was measured. Values represent means S.E. of three deter-
minations. (D) Keratinocytes were co-stimulated with both 10 lmol/L
histamine and 10 lg/mL PGN for 24 h. Amount of GM-CSF in
each sample was measured. Values represent means S.E. of three
determinations.
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responsible for TLR2 signaling. However, based only on the
present studies, we cannot exclude the existence of target
molecule for PGN other than TLR2 on keratinocytes. At least,
we conﬁrmed that PGN, which was used in this study, actually
stimulated NF-jB-inducible luciferase reporter activity using
HEK293 cells expressing TLR2 (data not shown).
MAPK pathways mediate survival, apoptosis, diﬀerentiation
and cytokine synthesis in keratinocytes [15–17]. In this study,
we found that PGN phosphorylated the three types of MAPK.
p38 MAPK is especially phosphorylated among three MAPKs,
and its downstream ATF2 was also phospholylated by PGN, in
consistent with the previous study using HEK 293 cells stably
expressing TLR2 [27]. The potency of stimulants for the in-
duction for GM-CSF expression correlated with that for the
phosphorylation of MAPKs, suggesting that MAPK pathways
are involved in GM-CSF expression. Pharmacological analysis
using the selective inhibitors of ERK and p38MAPK pathways
showed that both activation of ERK and p38MAPK play roles
in PGN-induced GM-CSF expression. In human monocytes,
ERK and p38MAPK co-operate in the LPS-induced GM-CSF
production through TLR4 [28]. Probably, the signaling systems
leading to GM-CSF generation is the common mechanism be-
tween TLR2 and TLR4. JNK was also stimulated by PGN.
JNK stimulates production of several cytokines in various cell
types [29], suggested that JNK may be involved in GM-CSF
expression. Moreover, NF-jB pathway critically regulates IL-8expression in keratinocytes via TLR2 [12–14,30]. Putative
binding site ofNF-jB locates on the promoter ofGM-CSF gene
[31]. Thus, MAPKs and NF-jB might contribute to an eﬃcient
GM-CSF gene expression in an interdependent or a synergistic
fashion. There is a possibility that these three MAPKs and NF-
jB participate in the induction of cytokines and chemokines
other than GM-CSF, and the precise mechanism of expression
of each mediators call for further research.
Since activation of ERK and p38 MAPK is required for
induction of GM-CSF synthesis in keratinocyte, a biologically
active substance, which activates either ERK or p38 MAPK,
appears to induce expression of GM-CSF. Histamine is re-
ported to activate ERK pathway and induce NGF production
via a histamine H1 receptor in keratinocytes [8]. Mast cells,
which degranulate abundant histamine, inﬁltrate into the
dermis in chronic AD [1]. As expected, histamine increased in
GM-CSF production from keratinocytes.
GM-CSF, which is overproduced from keratinocytes AD [2],
is essential for survival, diﬀerentiation and maturation of DC
and LC [2–6] and has also mitogenic eﬀects on keratinocytes
itself [32]. Eﬀects of GM-CSF on the antigen presenting cells
shift the immune response to Th2-type, and eﬀects of it on
keratinocytes make epidermal hypertrophy, which is charac-
teristic in chronic inﬂammation. Furthermore, the numerous
mediators induced by PGN are believed to contribute to the
development of skin disorders [7,10,18–21]. Immunobiochem-
ical causes of inﬂammatory skin disease, such as AD and
psoriasis, are believed to be very intricate. It is quite likely that
there are numerous inducers for production of cytokines and
chemokines from keratinocytes. Indeed, we found histamine as
the candidate other than PGN.Moreover, PGN augmented the
histamine-induced GM-CSF production signiﬁcantly. There-
fore, we speculate that this synergistic stimulation of kerati-
nocytes may develop a more serious form of the disease under
pathologic condition. More detailed examination of interaction
keratinocyte with PGN and histamine should provide clues as
to the underlying cause of inﬂammatory skin diseases.
In conclusion, our ﬁndings suggested that PGN of infected S.
aureus stimulates directly cytokine production from epidermal
keratinocytes in concert with biologically active substances like
histamine, leading to the chronic inﬂammation with inﬂamma-
tory skin disease. A further direction of this study will clinically
be to clarify the correlation between the severity of S. aureus
infection and amount of keratinocyte-derived cytokines.References
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